Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ENERGI-F705 is a small molecule drug developed by Energenesis Biomedical. It acts as an agonist of AMP-activated protein kinase (AMPK), stimulating this enzyme to exert therapeutic effects. The drug is being investigated primarily for the treatment of Parkinson's disease, with additional preclinical research in metabolic, neurodegenerative, mitochondrial, and skin disorders. Its mechanism involves activation of AMPK, which plays a key role in cellular energy homeostasis and may have anti-inflammatory and neuroprotective effects. As of early 2025, it has entered phase 1 clinical trials as an oral medication for Parkinson's disease[1][2][3][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ENERGI-F705.